Canada: Pharmacapsules @ Gowlings – May 2006

Last Updated: May 4 2006

Edited by Jane Steinberg and Ken Clark

  • U.S. FTC To Study Authorized Generics
  • Convention on Biological Diversity: Update
  • Natural Health Products - NPN Pending
  • EU Approves First Biogeneric
  • U.S. FDA To Develop Guidelines on Follow on Protein Biologics
  • Recent Cases

U.S. FTC To Study Authorized Generics

The U.S. Federal Trade Commission announced its intention to study the use and competitive effects of "authorized generics" - a drug that is chemically identical to the brand name drug and authorized by the brand name manufacturer to be marketed as a generic product version.

The Commission will examine wholesale prices, business reasons to support authorized generics, factors relevant to the decisions of generic firms to engage in such an arrangement, and licensing agreements between brand name companies and authorized generics.

Comments are being accepted until June 5, 2006.

For more information, please see:
http://communitydispatch.com/artman/publish/article_4394.shtml

Convention on Biological Diversity: Update

Last month, some 4,000 delegates from around the world gathered in Curitiba, Brazil to review progress in international efforts aimed at the conservation and sustainable use of biological diversity. Representatives of the 188 States Parties to the Convention on Biological Diversity and other interested groups met from March 20-31. The meeting covered a broad agenda and resulted in the adoption of some 30 major decisions, including an agreement to finalize by 2010 the negotiation of an international regime for access to and benefit-sharing of genetic resources.

The Convention on Biological Diversity was adopted at the Earth Summit in Rio de Janeiro in 1992 and came into force in 1993. It sets out commitments for maintaining the world's ecological variability in order to meet the need for food security, medicines, fresh air and water, and a healthy environment. The principal objectives of the Convention are the conservation and sustainable use of biological diversity and the fair and equitable sharing of benefits arising from its utilization. Canada was one of the first countries to ratify the Convention.

Ministers, business leaders and the largest-ever representation of civil society at a biodiversity-related meeting (over 1000), as well as representatives of the indigenous and local communities, participated in the meeting. Various themes were covered, including the increasing demand for food and associated land degradation and pesticide pollution, the pressure on biodiversity resulting from increased trade and the contribution of subsidies to overproduction, access to genetic resources subject to prior informed consent of the country providing such resources, and sharing upon mutually agreed terms with the country providing genetic resources the results of research and development arising from the commercial utilization of such resources .

The Director-General of the World Trade Organization, Pascal Lamy, addressed the meeting and spoke of rewarding innovative pharmaceutical companies that contribute to the maintenance of genetic diversity. Mr Lamy referred to the "medicinal stockpile" that is the rainforests and reminded the international gathering of the importance of using intellectual property rights judiciously. He said "it is incumbent on all countries to use intellectual property rights in a manner that fosters biodiversity."

Participants also agreed to seek to engage the private sector in efforts to curb biodiversity loss through the development of guidelines, certification and best practices.

The next meeting of the States Parties to the Convention will be in Germany in 2008.

Natural Health Products - NPN Pending

If you examine product labels on the shelf of your local health food store in Canada, you will note that there are a variety of natural health products that do not have product licences. When a company applies for a product licence, and is approved by the Natural Health Products Directorate (NHPD), the NHPD issues a natural product number, usually referred to as an NPN. The NPN is then included on the product label. The companies selling products without an NPN are either making no attempt to comply with Canadian law or are selling their products pursuant to the enforcement policies of the NHPD.

Selling products pursuant to the enforcement policies of the NHPD does not make the products "legal"; however, the enforcement policies offer insight into when Health Canada will restrain the marketing of such products. Under the enforcement policies, if a company applies for a NPN, receives a submission tracking number, is otherwise compliant with the Natural Health Product Regulations, and there are no risks or deemed risks to the health and safety of Canadians, then Health Canada will not focus its enforcement on those products. The fact that an NPN is pending not only does not make the sale of a product legal, but it does not provide a legal basis for challenging an enforcement action. It merely provides a company with the ability predict the likelihood of enforcement.

Some companies have included the words "NPN Pending" on product labels while the products are sold based on the enforcement policies. The NHPD takes the position that including the words "NPN Pending" on a product label is misleading, false, or deceptive to consumers and thus in direct violation of the Food and Drugs Act. On April 10, 2006, the NHPD reiterated its position regarding the use of "NPN Pending" product labels in a NHPD bulletin, asking companies to immediately cease this activity.

The NHPD considers the use of "NPN Pending" to be misleading because the mere application for a NPN is not determinative of whether the NHPD will actually issue a NPN. Depending on the type of product, there are a variety of issues that the NHPD will consider, the most obvious consideration being whether the evidence submitted demonstrates that the product works for its intended purpose. The NHPD takes the position that including the words "NPN Pending" implies that the application has been accepted and it is just a matter of time until the NPN will be issued, when in fact the NPN may never be issued for the product as submitted.

EU Approves First Biogeneric

The EU has approved the first biosimilar product, Sandoz's OMNITROPE. The new regulatory framework under which the product was approved allows the regulatory authority to approve copies of biologic drugs without a full dossier of clinical data.

The approval puts pressure on the U.S. Food and Drug Administration (FDA) that has been sued for delaying an application to market the Sandoz product in the U.S. Recently, a federal judge ordered the FDA to decide on the dossier that was filed in July 2003. The judge required the FDA to set out a clear regulatory framework for this type of product in the U.S.

For more information, please see:
http://www.pharmatimes.com/news/190406c.aspx?src=PharmaTimes&fr=1

U.S. FDA To Develop Guidelines on Follow on Protein Biologics

In a letter recently made public, the U.S. Food and Drug Administration (FDA) has indicated that it will focus on general guidelines about follow on protein products rather than issuing guidelines on specific biologic drugs. The generic industry has been waiting for the agency's advice on how to best test alternative versions of insulin and human growth hormone, and was expecting to learn from anticipated guidelines the FDA's requirements to assist them in seeking product approval. The letter indicated "After reassessing these product-specific documents, FDA has decided that it would be more appropriate to publish guidances which are more broadly applicable to (follow-on protein products) in general". Apparently, several generic biologics have been approved even without guidelines in place.

For more information, please see:
http://www.kpmginsiders.com/display_reuters.asp?cs_id=156775

Recent Cases

Abbott v. Pharmascience; March 16, 2006, 55.2 Proceeding

- the Court granted prohibition on the basis of resjudicata

- the generic manufacturer had alleged the invalidity of the patent at issue in a prior proceeding. Those allegations dealt with the issue of over breadth. In the current NOA, the allegations related to obviousness and anticipation.

- the Court held that the generic manufacturer was required to use reasonable diligence to bring forth, in the first instance, all points that relate to the invalidity of the patent.

The text of the decision can be found at:
http://decisions.fct-cf.gc.ca/fct/2006/2006fc341.shtml

Biovail v. Canada (Minister of National Health and Welfare, March 13, 2006, Court of Appeal, Listing Issue

- the Court dismissed an appeal of a judicial review of a Minister's decision not to list a patent on the Patent Register.

- the patent at issue claimed a controlled release formulation.

- the Court construed the claims for the use of the formulation to achieve the slow release of the active ingredient; thus, the claimed invention was not for the medicine itself.

The full text of this decision can be found at:
http://decisions.fca-caf.gc.ca/fca/2006/2006fca105.shtml

Procter & Gamble v. Canada; March 30, 2006, Listing Issue

- the Court dismissed a judicial review of the Minister's decision not to list patents on the Patent Register.

- one patent at issue claimed a film coated formulation and the other claimed an enteric coated formulation.

- the Court held that when determining whether the patent at issue covered a formulation or a device, the Court should consider whether the patent claims a "delivery system" versus a "payload". Claims to a delivery system are not claims to the medicine itself.

The full text of this decision can be found at:
http://decisions.fct-cf.gc.ca/fct/2006/2006fc411.shtml

Purdue v. Novopharm, March 29, 2006, 55.2 Proceeding, Interlocutory Motion

- the Applicants appealed the Prothonotary's order refusing to strike portions of affidavit evidence and refusing reply evidence; the Court dismissed the appeal.

- the Court held that a motion to ignore evidence and a motion to Strike are practically indistinguishable.

- the Court also held that, in order to file reply evidence, it must be demonstrated that the further evidence will serve the interests of justice.

The full text of this decision can be found at:
http://decisions.fct-cf.gc.ca/fct/2006/2006fc385.shtml

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions